Hormone Replacement Therapy Market Outlook 2026: Key Vendors, Growth Factors And Market Share Forecast Offered In Latest Report Estmated By Global Players Novartis Ag, Abbott Laboratories, Mylan N.V., Merck Kgaa, Bayer Ag, Pfizer Inc.

New mergers and acquisitions is one of the major factor driving the growth of the hormone replacement therapy market. For instance, in 2014 Pfizer Inc., a U.S.-based pharmaceutical company, merged with OPKO Health Inc., a U.S.-based company, to develop a long acting growth hormone (hGH-CTP) and innovative treatments for growth hormone deficient patients. hGH-CTP is more convenient, as the patients need to take just one injection in a week rather than daily doses. hGH-CTP has an orphan drug designation in the U.S. and Europe for adults and children with growth hormone deficiency.

For In depth Information Get Sample Copy of this Report at: https://www.coherentmarketinsights.com/insight/request-sample/2079

Robust pipeline is also expected to support growth of the hormone replacement therapy market size. For instance, Somapacitan sponsored by Novo Nordisk A/S, a Denmark-based company, completed phase 3 clinical trials in 2017. This drug is used for the treatment of growth hormone deficiency in adults.

The global hormone replacement therapy market size was valued at US$ 10.58 billion in 2017 and is expected to witness a CAGR of 5.2% over the forecast period (2018 – 2026).

Market Dynamics:

Increasing number of people suffering from hypogonadism and rising adoption of testosterone products in various economies is expected to propel overall growth of the market. According to the data published in the European Association of Urology Journal: 2017, testosterone prescription trends in the U.S. exhibited an increase between 1.8- and 4-fold over the last two decades (1997 - 2017). Moreover, from 2000 to 2011, there was a 4.3-fold increase in testosterone testing when compared to a 3.7-fold increase in prescriptions.
Rising number of generic versions of hormone replacement therapies by various manufacturers will drive growth of the market in terms of volume and value. For instance, Teva Pharmaceutical Industries Ltd. launched the generic Axiron1 (testosterone) topical solution CIII, 30 mg/1.5 mL, in the U.S. on August 18, 2017 to treat adult males who have low or no testosterone due to certain medical conditions. This solution was supplied in a metered dose pump with an underarm applicator.

However, high cost associated with the replacement therapy and complex reimbursement scenario that causes excluding of the therapy from coverage by insurers, as it is a rare disease, hampers growth of the hormone replacement therapy market.

Increasing prevalence of various chronic conditions are expected to drive growth of the hormone replacement therapy market:

Increasing prevalence of hypogonadism in adult men worldwide is expected to drive growth of the hormone replacement therapy market.

According to the European Association of Urology: 2016 report, in middle-aged men, the incidence of hypogonadism varies from 2.1% to 12.8%. The incidence of low testosterone and symptoms of hypogonadism in men aged 40-79 varies form 2.1% to 5.7%, in Europe.
Ease in access and government support for research and development activities is expected to aid in growth of the hormone replacement therapy market. Financial help by NGOs such as the National Gaucher Society help patients receive enzyme replacement therapy that are costly.

Hormone Replacement Therapy Market - Regional Insights:

On the basis of region, the global hormone replacement therapy market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global hormone replacement therapy market, owing to continuous launch of various generic products for hormone replacement therapies by manufacturers.
Furthermore, Europe is expected to be the second largest contributor to the hormone replacement therapy market, in terms of revenue and is expected to gain significant traction in the near future. This is owing to launch of new drugs and therapies to combat secondary hyperparathyroidism and presence of significant population suffering from the disease in this region.

For instance, in December 2016, Amgen’s drug etecalcetide (Parsabiv) received marketing approval in Europe by the European Commission for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney diseases.
Asia Pacific is expected to witness fastest growth over the forecast period, owing to increasing healthcare associated issues with rising incidence of chronic diseases, high prevalence of hypogonadism in men with type II diabetes mellitus, and rising prevalence of diabetes population in this region.

For instance, according to the International Diabetes Federation (IDF) Diabetes Atlas: 2017, number of people suffering from diabetes aged between 20 to 79 years in South East Asia region and Western Pacific region in 2017, was 82 million and 159 million, respectively.

Browse Research Report At: https://www.coherentmarketinsights.com/market-insight/hormone-replacement-therapy-market-2079

Global Key Players:

Key players operating in the global hormone replacement therapy market include
Novartis AG
Abbott Laboratories
Mylan N.V.
Merck KgaA
Bayer AG
Pfizer Inc.
Novo Nordisk A/S
QuatRx Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
Amgen, Inc.
Eli Lilly and Company.

Detailed Segmentation:

Global Hormone Replacement Therapy Market, By Therapy Type:
Estrogen Replacement Therapy
Human Growth Hormone (HGH) Replacement Therapy
Thyroid Replacement Therapy
Testosterone Replacement Therapy

Global Hormone Replacement Therapy Market, By Route of Administration:
Oral
Parenteral
Others

Global Hormone Replacement Therapy Market, By Application:
Hypothyroidism
Male Hypogonadism
Growth Hormone Deficiency
Menopause
Others

Global Hormone Replacement Therapy Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Hormone Replacement Therapy Market, By Region:
North America
Europe
Asia Pacific
Latin America
Middle East
Africa

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/2079

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below linkor contact at sales@coherentmarketinsights.com

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.